CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL
Phase 2 Study of CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19) for Adult Patients With Minimal Residual Disease During Upfront Treatment for Acute Lymphoblastic Leukemia
Sponsor: University of Pennsylvania
Terminated
Study is terminated because of administrative reasons.
Other terminated trials from University of Pennsylvania
Other Leukemia, Acute Lymphoblastic trials with similar outcome
A PHASE2 clinical study on Leukemia, Acute Lymphoblastic, this trial is terminated or withdrawn. The trial is conducted by University of Pennsylvania and has accumulated 15 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2023 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
▶ Show 10 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Dec 2019 — Mar 2020 [monthly]
Terminated PHASE2
-
Mar 2019 — Dec 2019 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Dec 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Nov 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .